CALZF Stock Chart & Stats
$0.76
-$0.78(-42.86%)
At close: 4:00 PM EST
$0.76
-$0.78(-42.86%)
Day’s Range― - ―
52-Week Range$0.55 - $0.92
Previous CloseN/A
Volume1.00K
Average Volume (3M)657.00
Market Cap
$439.46M
Enterprise Value$624.48M
Total Cash (Recent Filing)$35.47M
Total Debt (Recent Filing)$17.61M
Price to Earnings (P/E)85.4
Beta2.18
Next Earnings
Mar 02, 2027EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding690,843,000
10 Day Avg. Volume1,000
30 Day Avg. Volume657
Financial Highlights & Ratios
PEG Ratio-1.95
Price to Book (P/B)7.01
Price to Sales (P/S)4.42
P/FCF Ratio67.26
Enterprise Value/Market Cap1.42
Enterprise Value/Revenue4.35
Enterprise Value/Gross Profit13.29
Enterprise Value/Ebitda63.31
Forecast
1Y Price Target
$0.81Price Target Upside6.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$113.52M
Bulls Say, Bears Say
Bulls Say
Broad Revenue And Account GrowthSustained double-digit product growth alongside a broader hospital customer base indicates expanding clinical adoption and market penetration. The combination supports recurring commercial momentum and gives PolyNovo a larger installed account platform from which to introduce products and deepen utilization.
Rapid MTX AdoptionMTX is growing substantially faster than the broader portfolio and is already spreading across U.S. hospitals and international markets. This creates a meaningful second growth engine, broadens the product platform, and can support future revenue mix improvement as adoption matures.
Improved Profitability And Cash GenerationThe move to stronger EBITDA and positive free cash flow demonstrates improving operating scale and internal funding capacity. Together with conservative leverage and $35.4M of cash, these results provide resources for facility investment, research, commercialization, and resilience through execution variability.
Bears Say
Margin VolatilityProfitability remains positive but is not yet consistently durable, with lower net margins and material gross-margin variation across periods. The facility transition may initially dilute margins further, making earnings more sensitive to product mix, utilization, and operating execution.
Regulatory And Reimbursement TimingExpansion into important U.S. indications depends on regulatory progress and provider confidence in reimbursement. Delays or policy friction could defer commercialization, slow adoption, and prolong investment requirements before the company realizes the expected benefits from outpatient and broader-market opportunities.
Competitive PressureGreater competitor activity can make hospital conversion and retention more difficult, particularly in expanding indications where purchasing decisions may be less established. Sustaining growth may therefore require continued clinical evidence, market-access work, and innovation to defend PolyNovo's position.
Polynovo News
CALZF FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest stock price was $0.55 and its highest was $0.92 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is $439.46M.
When is Polynovo Limited’s upcoming earnings report date?
Polynovo Limited’s upcoming earnings report date is Mar 02, 2027 which is in 122 days.
How were Polynovo Limited’s earnings last quarter?
Polynovo Limited released its earnings results on Aug 25, 2026. The company reported $0.009 earnings per share for the quarter, beating the consensus estimate of $0.006 by $0.003.
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate is <0.01.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Polynovo Limited reported an EPS of $0.009 in its last earnings report, beating expectations of $0.006. Following the earnings report the stock price went down -4.227%.
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in CALZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$0.81 (6.05% Upside)
$0.81 (6.05% Upside)
Blogger Sentiment
Bullish
CALZF Sentiment 95%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.71%
12-Months-Change
Fundamentals
Return on Equity
8.45%
Trailing 12-Months
Asset Growth
8.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Polynovo Limited
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
CALZF Company Deck
CALZF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates strong commercial momentum across products (notably MTX), significant sales and adjusted EBITDA growth, positive cash generation and strategic investments (new facility, strengthened leadership, clinical evidence). Several manageable near-term headwinds were disclosed: FX volatility, one-off impacts from an R&D lab fire, lumpy large-burn case volumes affecting H2 U.S. growth, reimbursement turbulence for outpatient launches, and timing risks tied to PMA approval and facility transition. Overall the positives (robust growth rates, record months, strong cash flow, substantial MTX adoption and regulatory progress) materially outweigh the challenges, which are largely operational, timing or one-off in nature.View all CALZF earnings summariesCALZF Stock 12 Month Forecast
Average Price Target
$0.81
▲(6.05% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―
Ownership Overview
0.22% Insiders
2.73% Mutual Funds
― Other Institutional Investors
93.66% Public Companies and
Individual Investors